For patients & payers: A step toward lower costs and broader access to proven obesity treatments For Teva Pharmaceuticals: A strategic move into one of the fastest-growing segments in global pharma For Novo Nordisk: Limited short-term impact, but mounting competitive pressure as generics gain ground This development could reshape affordability, accessibility, and competition in obesity care signaling the beginning of a new chapter for patients and healthcare systems worldwide
Abebe TB, Gebreyohannes EA, Tefera YG, Abegaz TM
PGC-1 is required for induction of many reactive oxygen species (ROS)-detoxifying enzymes and has been shown to grant neuroprotection against MPTP and kainic acid in other studies (89)
Reduced overall food intake during the early weeks of treatment compounds the effect by reducing the bulk that normally drives colonic propulsion
Escalation: Move to 4 mg weekly for Weeks 58, then 8 mg weekly for Weeks 912 [1]
Monitoring: Regular check-ins with a professional allow for adjustments based on how your body responds to the treatment
